Holen Sie sich die Stockscreener-App
27.84
2.90%
-0.83
Handel nachbörslich:
28.00
0.16
+0.57%
Rapport Therapeutics Inc Aktie (RAPP) Neueste Nachrichten
(RAPP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives $50.80 Consensus PT from Brokerages - Defense World
Equities Analysts Offer Predictions for RAPP FY2030 Earnings - MarketBeat
Capital International Investors Buys 800,000 Shares of Rapport Therapeutics, Inc. $RAPP - MarketBeat
Day Trade: Will Rapport Therapeutics Inc stock go up in YEARMarket Weekly Review & Scalable Portfolio Growth Methods - baoquankhu1.vn
Rapport Therapeutics (NASDAQ:RAPP) Price Target Raised to $46.00 at Wells Fargo & Company - MarketBeat
Stifel reiterates Rapport Therapeutics stock rating after results By Investing.com - Investing.com Canada
Rapport Therapeutics Inc (RAPP) Reports a Wider Loss for Q4 2025 - AlphaStreet
Rapport Therapeutics Reports Strong 2025 Results, Advances RAP-219 Epilepsy Drug to Phase 3 with $490M Cash Runway - Minichart
Rapport’s RAP-219 gets more phase III funding with Tenacia deal - bioworld.com
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Down on Disappointing Earnings - MarketBeat
Rapport Therapeutics: Advancing Precision Neuroscience with RAP Technology Platform for Neurological and Psychiatric Disorders 4048 - Minichart
Earnings Flash (RAPP) Rapport Therapeutics Posts Q4 Net Loss $0.72 a Share, vs. FactSet Est of $0.70 Loss - marketscreener.com
Rapport Therapeutics (NASDAQ:RAPP) Posts Quarterly Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
Rapport Therapeutics 2025 10‑K: Net loss $111.5M, EPS $(2.86) - TradingView
RAP-219 epilepsy drug cut seizures 77.8% in Phase 2a trial - Stock Titan
Citizens reiterates Rapport Therapeutics stock rating on seizure drug potential By Investing.com - Investing.com Canada
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Maintained Buy: RAPP analyst rating on Rapport Therapeutics, Inc. Common Stock Mar 2026 - Meyka
Top Executive’s Surprise Stock Move Shakes Up Rapport Therapeutics - TipRanks
Cheryl Gault Sells 2,014 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
BTIG reiterates Rapport Therapeutics stock rating citing selectivity By Investing.com - Investing.com Canada
Rapport Therapeutics stock holds Buy at TD Cowen on China deal - Investing.com Canada
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China - Bitget
China rights deal backs new epilepsy, bipolar drug RAP-219 - Stock Titan
How Rapport Therapeutics Inc. stock reacts to bond yieldsJuly 2025 Catalysts & Expert Curated Trade Setup Alerts - Naître et grandir
Published on: 2026-03-07 16:24:29 - baoquankhu1.vn
Is Rapport Therapeutics Inc. stock oversold or undervalued2025 Technical Overview & Weekly High Conviction Trade Ideas - Naître et grandir
Rapport Therapeutics Inc expected to post a loss of 68 cents a shareEarnings Preview - TradingView
Risks Report: Is Rapport Therapeutics Inc a stock for growth or value investorsWeekly Trend Recap & Expert Approved Trade Ideas - baoquankhu1.vn
TD Asset Management Inc Has $4.07 Million Stock Holdings in Rapport Therapeutics, Inc. $RAPP - MarketBeat
Rapport Therapeutics (RAPP) to Release Quarterly Earnings on Tuesday - MarketBeat
RAPP Should I Buy - Intellectia AI
Liquidity Mapping Around (RAPP) Price Events - Stock Traders Daily
RAPP PE Ratio & Valuation, Is RAPP Overvalued - Intellectia AI
Rapport Therapeutics (NASDAQ:RAPP) Raised to Hold at Wall Street Zen - MarketBeat
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Unveiling a 73.63% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Buyout Rumor: What is the cash position of Rapport Therapeutics Inc2025 Macro Impact & Short-Term High Return Ideas - baoquankhu1.vn
Rapport Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Highs Report: What hedge funds are buying Rapport Therapeutics IncGap Down & Consistent Return Investment Signals - baoquankhu1.vn
RAPP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rapport Therapeutics, Inc. (RAPP) Investor Outlook: Analyzing A 70.80% Potential Upside - DirectorsTalk Interviews
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $246,670.00 in Stock - MarketBeat
Why (RAPP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
RAPP Stock Price and Chart — NASDAQ:RAPP - TradingView
We're Not Very Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn Rate - Yahoo Finance
Can Rapport Therapeutics Inc. stock deliver surprise earnings beatMarket Sentiment Review & Weekly High Momentum Picks - mfd.ru
RAPP Technical Analysis & Stock Price Forecast - Intellectia AI
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A Deep Dive Into Its 83% Potential Upside - DirectorsTalk Interviews
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Does Rapport Therapeutics Inc. have strong fundamentals2025 Price Action Summary & Technical Pattern Based Signals - mfd.ru
Will Rapport Therapeutics Inc. stock split again soonInsider Selling & Precise Trade Entry Recommendations - mfd.ru
Understanding Momentum Shifts in (RAPP) - Stock Traders Daily
RSI Check: What hedge funds are buying Rapport Therapeutics IncM&A Rumor & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
A Look At Rapport Therapeutics (RAPP) Valuation After Fresh Overweight Rating From Wells Fargo - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Stock Rating Lowered by Wall Street Zen - MarketBeat
Rapport Therapeutics, Inc. (RAPP) Investor Outlook: A 100% Upside Potential In Biotech Sector - DirectorsTalk Interviews
Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next - TipRanks
Rapport Therapeutics (NASDAQ:RAPP) Now Covered by Analysts at Wells Fargo & Company - Defense World
Wells Fargo Initiates Coverage of Rapport Therapeutics (RAPP) with Overweight Recommendation - Nasdaq
Rapport Therapeutics (RAPP): Analyst Initiates Coverage with Ove - GuruFocus
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):